Cutaneous T-cell Lymphoma Stage I

Stage I cutaneous T-cell lymphoma represents early-stage disease where cancer affects less than 10% of the skin, with no involvement of the blood, lymph nodes, or internal organs, offering patients a favorable outlook with many living normal lives for decades.

Table of contents

• What is Cutaneous T-cell Lymphoma?
• Understanding Stage I Disease
• Symptoms and How It Appears
• How Stage I CTCL is Diagnosed
• Outlook and Survival
• Treatment Options for Stage I
• Living with Stage I CTCL

What is Cutaneous T-cell Lymphoma?

Cutaneous T-cell lymphoma (CTCL) is a rare type of blood cancer that affects the skin. It happens when certain white blood cells called T lymphocytes (T cells), which normally help fight infections throughout the body, become cancerous and collect in the skin^[1].

CTCL is not a skin cancer like melanoma. Instead, it is a type of blood cancer called non-Hodgkin lymphoma that shows up on the skin^[7]. The most common form of CTCL is called mycosis fungoides, which accounts for about half of all CTCL cases^[3]. Despite its name, mycosis fungoides has nothing to do with fungal infection.

CTCL is quite rare. Approximately 3,000 new cases are diagnosed in the United States each year^[8]. The disease is more common in men than women and usually occurs in people over 50 years of age^[5]. Many people have symptoms for years before receiving a proper diagnosis because CTCL can look like other common skin conditions such as eczema or psoriasis^[4].

Understanding Stage I Disease

CTCL is classified into different stages based on how much of the body is affected. The staging system uses letters and numbers to describe the amount of skin involved (T), whether lymph nodes are affected (N), whether the disease has spread to other organs (M), and whether cancer cells are found in the blood (B). This is called the TNMB system^[1].

Stage I disease is considered early-stage CTCL and is divided into two categories^[1]:

• Stage IA: Less than 10% of the skin is covered in red patches or plaques, and there is no blood, lymph node, or internal organ involvement.
• Stage IB: 10% or more of the skin is covered in patches or plaques, and there is no blood, lymph node, or internal organ involvement.

Stages IA, IB, and IIA are all considered early-stage disease. In contrast, stages IIB through IVB are considered advanced-stage disease, where the cancer is more widespread or has moved outside the skin to other places in the body such as the lymph nodes or other organs^[1].

Symptoms and How It Appears

In stage I CTCL, particularly mycosis fungoides, the disease typically appears as patches or plaques on the skin. These skin changes can easily be mistaken for other common skin problems^[4].

The typical appearance includes well-defined, reddened, asymmetrical patches and plaques. These often have a thin, wrinkled surface appearance with fine scales. They usually appear on areas of the body that are not exposed to the sun, particularly around the pelvic area^[4].

Common symptoms include^[7]:

• Red, scaly, itchy patches on the skin
• Flat or slightly raised areas of discolored skin
• Dry skin
• Itching, which can sometimes be severe

In some people, especially those with deeply pigmented skin, the patches may appear lighter than the surrounding skin rather than red^[4].

How Stage I CTCL is Diagnosed

Diagnosing CTCL can be challenging because it looks like many other skin conditions. Getting the correct diagnosis may take time and often requires repeated testing^[9].

The diagnosis process typically includes^[1]:

• Physical examination: A thorough exam of the entire skin surface, looking for patches, plaques, or other changes
• Skin biopsy: Removal of a small piece of affected skin to examine under a microscope. A doctor who specializes in studying tissues, called a pathologist, examines the sample to look for cancer cells
• Blood tests: To check for cancer cells in the blood and evaluate overall health

Additional tests that might be performed include examination of lymph nodes, bone marrow testing, and imaging tests such as CT scans (computerized pictures of the inside of the body) or PET scans (special scans that show areas of high activity in the body)^[1].

Because CTCL can be confused with other conditions, it is important to work with doctors who have experience with this disease. Several skin biopsies may be needed before the diagnosis is confirmed^[4].

Outlook and Survival

Stage I CTCL generally has a very favorable outlook. The disease is usually slow-growing and can progress over years or even decades^[4].

For people with stage IA disease, the outlook is particularly good. The median survival is 20 years or more, and most deaths in this group are not caused by or related to the lymphoma^[6]. This means that many people with stage IA disease live normal lifespans and die of causes unrelated to CTCL.

Some patients with early-stage CTCL might not progress to later stages at all, while others might progress more rapidly. The course of the disease varies from person to person^[3].

The presence of certain factors can affect the outlook. Research has identified four markers that indicate a worse survival: stage IV disease, age older than 60 years, transformation to large cells, and elevated levels of an enzyme called lactate dehydrogenase^[6]. However, these factors are more relevant to advanced disease than to stage I.

Treatment Options for Stage I

Treatment for stage I CTCL focuses on controlling symptoms and managing the disease on the skin. The goal is to provide relief while minimizing side effects, since many people will live with this condition for a long time^[1].

Skin-Directed Therapies

For stage I disease, skin-directed therapies are the main treatment approach. These are treatments that work on or near the surface of the skin without much absorption into the bloodstream, so they often have minimal side effects^[14].

Common skin-directed treatments include^[11][14]:

• Topical corticosteroids: Steroid creams that reduce inflammation and directly kill lymphoma cells. These can help reduce itching
• Topical chemotherapy: Medications like mechlorethamine (also called nitrogen mustard) that are applied to the skin. A gel form called Valchlor is specifically approved for CTCL
• Phototherapy: Treatment with ultraviolet light. This can include narrowband UVB light for thin patches or PUVA (a combination of a drug called psoralen with UVA light) for thicker plaques
• Local radiation therapy: Focused radiation beams directed at affected areas of skin

Complete remission rates of 80-90% have been reported with ultraviolet light therapy in early-stage disease^[15].

Additional Treatment Options

Other treatment options that may be used for stage I disease include^[11]:

• Topical retinoids: Vitamin A-related medications applied to the skin, such as bexarotene gel (Targretin)
• Imiquimod: A cream that stimulates the immune system in the skin

For people with very limited areas of involvement, surgical removal or localized radiation may be options^[15].

In addition to specific treatments for CTCL, supportive care is important. This includes using moisturizers to help with dry skin and medications to control itching^[15].

Living with Stage I CTCL

Stage I CTCL is generally considered a chronic condition that can be managed over time. Many people with early-stage disease are able to maintain their normal daily routines while receiving treatment^[11].

Physical Challenges

People with CTCL may experience several physical symptoms^[17]:

• Severe itching that may interfere with sleep
• Skin that feels hot or sore
• Flaking or burning skin
• Difficulty finding comfortable clothing

The disease can have a pattern of outbreaks and remissions. During outbreaks, symptoms may be intense and uncomfortable. During periods of remission, which can sometimes last many years, people may feel that the disease is entirely manageable^[17].

Emotional and Social Aspects

Being diagnosed with any form of cancer can bring up many emotions, from disbelief to fear. Many people experience denial when first hearing the diagnosis^[17].

Because CTCL affects the skin, visible patches or plaques may appear on areas that others can see, such as the face, neck, or legs. This can affect how people feel about their appearance^[17].

It’s important to remember that CTCL is not contagious and cannot be spread to other people^[7].

Managing Your Care

Working closely with your healthcare team is essential. This may involve trying different treatments to find what works best for you. Treatments may need to change over the course of living with the disease, and new treatment options are steadily becoming available^[17].

Talking with trusted friends and family, your healthcare team, and others close to you can help with the challenges of living with CTCL^[17]. Support groups and patient organizations can also provide valuable information and connection with others who understand the experience of living with this condition.